COPD — all decisions

The Board denied the Veteran's claim for service connection for chronic obstructive pulmonary disease (COPD) as there was no persuasive evidence that it was related to his active-duty service. The claim for bilateral hearing loss was remanded due to incomplete audiometric data.

The Board granted service connection for chronic obstructive pulmonary disorder (COPD) and chronic bronchitis pursuant to the PACT Act, denied service connection for chronic sinusitis, and remanded several other claims including those related to gastrointestinal issues, pancreatitis, and hip strains.

The Board remands the issues for additional development, including reissuing a rating decision and notification letter.

The Board remands the claims for service connection for COPD, Parkinson's disease, and peripheral neuropathy of all extremities to schedule examinations to determine if there is a relationship between these conditions and the Veteran's presumed exposure to herbicides during his service in Vietnam.

The Board denied the Veteran's claim for service connection for chronic obstructive pulmonary disease (COPD), finding that the evidence did not support a link between COPD and his military service, including any toxic exposure risk activities during service.

The Board denied the veteran's claims for an initial compensable evaluation for hypothyroidism and service connection for chronic obstructive pulmonary disease (COPD).

The Board granted service connection for chronic obstructive pulmonary disease (COPD) and remanded the claim for service connection for emphysema.

The appeal for a higher initial rating for asthma with COPD was dismissed as the Veteran's attempt to appeal the June 2024 rating decision did not meet the necessary procedural requirements.

The Board granted service connection for an acquired psychiatric disorder and a respiratory condition, but denied service connection for chloracne. The Veteran's bladder cancer was rated at the maximum schedular rating of 100 percent, and an earlier effective date for DEA benefits was also denied.

The Board denied service connection for chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), finding no evidence of a current disability or a nexus to service.

The Board remands the matter for additional development, including obtaining addendum opinions regarding whether the Veteran's COPD is etiologically related to in-service inhalation of chemical substances and toxic exposure risk activity (TERA), specifically asbestos exposure.

The Board denied the Veteran's claim for service connection for chronic obstructive pulmonary disease (COPD), finding that the evidence does not support a link between his in-service exposures and his current COPD.

The veteran's appeal requests for service connection for vocal cord cancer, dementia, neck cancer, and COPD were dismissed as untimely.

The Board granted an initial disability rating of 100 percent for the Veteran's service-connected COPD, effective May 15, 2017.

The Board remands the claims for service connection for COPD and peripheral neuropathy of the bilateral upper and lower extremities, including as due to herbicide agent exposure, because the VA medical opinions are inadequate.

The Board remands the claims for service connection for GERD and COPD to obtain a more detailed VA medical opinion, as the previous opinions were found inadequate.

The Board granted service connection for COPD, bladder cancer, and a heart condition due to in-service exposure to asbestos and lead paint.

The Board granted service connection for chronic obstructive pulmonary disease (COPD) based on the Veteran's conceded in-service asbestos exposure.

The Board denied service connection for an acquired psychiatric condition, to include PTSD, and remanded claims for asthma, COPD, a low back condition, and sleep apnea due to inadequate medical evidence.

The Board remands the matter for a new medical examination to determine the nature of the Veteran's COPD and to obtain any necessary pulmonary function test (PFT) or DLCO testing.